Abdallah Geara, MD

Abdallah Geara, MD, is an Associate Professor of Clinical Medicine at the University of Pennsylvania.

Articles by Abdallah Geara, MD

IgAN Pathogenesis: How Each Drug Class Targets the Multi-Hit Pathway

ByShikha Wadhwani, MD, MS,Chee Kay Cheung, MBCHB, MRCP, PhD,Abdallah Geara, MD

November 6th 2026

IgAN arises through a multi-hit process, and each therapeutic class acts at a different step. Dr. Cheung maps mucosal B-cell priming, plasma cells, complement, and kidney-protective therapies onto the pathway.

IgAN Treatment Escalation: Beyond Supportive Care and Access Barriers

ByShikha Wadhwani, MD, MS,Chee Kay Cheung, MBCHB, MRCP, PhD,Abdallah Geara, MD

November 6th 2026

Guidelines now call for treating the immune driver of disease and providing supportive care at the same time. The panel considers how ambitious targets have become realistic, and why access still limits what clinicians can offer.

IgAN Progression Risk: Proteinuria, eGFR Decline, and the Role of Hematuria

ByShikha Wadhwani, MD, MS,Chee Kay Cheung, MBCHB, MRCP, PhD,Abdallah Geara, MD

October 30th 2026

Despite new therapies, IgAN still progresses to kidney failure in most patients. The panel reviews who is at greatest risk, which targets matter, and how hematuria fits alongside proteinuria and eGFR.

IgAN Enters “Mechanism-First Era” Reframing Diagnosis, Treatment, and Remission

ByEdgar Lerma, MD,Abdallah Geara, MD,Corey Cavanaugh, DO

May 15th 2026

On IgAN Awareness Day, clinicians highlight earlier diagnosis, dynamic risk stratification, and emerging targeted therapies reshaping care.

2 IgA Nephropathy Experts Explain Clues For Early Intervention and Diagnosis

ByAbdallah Geara, MD,Corey Cavanaugh, DO

March 27th 2026

Corey Cavanaugh, DO, and Abdallah Geara, MD, separately share their perspectives on the clinical clues for IgAN diagnosis, including hypertension and microscopic hematuria.